Future role of topotecan in the treatment of lung cancer

Topotecan (HYCAMTIN (R); GlaxoSmithKline, Brentford, Middlesex, UK) is a no vel topoisomerase I inhibitor with potentially broad applicability in the t reatment of solid and hematologic malignancies. In addition to its use in r elapsed small-cell lung cancer (SCLC), topotecan is under investigation in numerous studies for first-line therapy in SCLC and for first- and second-l ine treatment of non-small-cell lung cancer (NSCLC). Preliminary evidence p resented in this supplement demonstrates that single-agent topotecan and to potecan-based combination regimens are active in these settings. In additio n to its potential use in SCLC and NSCLC, the feasibility and antitumor act ivity of topotecan as single-agent therapy and in combination therapy are u nder active investigation in a variety of other solid and hematologic tumor s. Other important avenues of investigation include the feasibility and tum or activity of a more convenient oral formulation, as well as the investiga tion of alternate regimens (e.g., 3-day, weekly), with high priority given to regimen toxicity, patient convenience, and quality of life. Preliminary results of some of these trials are presented in this summary. The results of other clinical experience trials are eagerly anticipated. Copyright (C) 2001 S. Karger AG, Basel.